Subscribe To
Dhs: experiencing the bust phase
The WisdomTree U.S. High Dividend Fund ETF focuses on high dividend-paying stocks. The DHS ETF's selection methodology creates large sector bets, whic...
May 15, 2023, 1:01 am
The race intensfies: google announces bold progress in ai, advancing med-palm 2 for healthcare
Med-PaLM 2 welcomes the next phase of healthcare data analysis and insight generation....
May 15, 2023, 12:36 am
Kymera: more data needed
Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety ...
May 14, 2023, 9:14 am
Meta's year of efficiency is working. but is all the good news priced into the stock?
Meta has executed the first phase of cost reductions. The company is focused on operational efficiency ...
May 14, 2023, 7:15 am
What to expect from fulgent genetics in 2023
We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its ...
May 14, 2023, 1:47 am
Corvus pharmaceuticals: targeting $1 billion/year u.s. t-cell lymphoma market
Additional phase 1b data for CPI-818 in T cell lymphoma is expected in this quarter. ...
May 12, 2023, 4:25 pm
Gold price forecast: xau/usd to suffer a phase of weakness during the summer months – commerzbank
GBP/USD has lost its recovery momentum and retreated below 1.2500 in the second half of the day on Friday. The persistent US Dollar (USD) strength ahe...
May 12, 2023, 3:44 pm
Why europe etfs may be better bets than u.s.
Europe investing has outperformed the United States in the initial phase of 2023. Cheaper valuation, up...
May 12, 2023, 9:10 am
Revive therapeutics halts bucillamine for covid-19 study; seeks data evaluation to inform next steps
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said its phase 3 clinical trial evaluating Bucillamine,...
May 12, 2023, 9:01 am
Immunitybio: anktiva rejection heightens financial urgency
ImmunityBio stock dropped over 50% after the FDA issued a CRL for Anktiva, their lead product for treating BCG-unresponsive non-muscle invasive bladde...
May 12, 2023, 5:20 am
Harpoon therapeutics reports first quarter 2023 financial results and provides corporate update
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended ...
May 11, 2023, 8:30 pm
Gracell biotechnologies to present clinical data on bcma/cd19 dual-targeting fastcar-t gc012f in rrmm and b-nhl and donor-derived car-t gc007g in b-all at eha2023 congress
First disclosure of data from phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% ove...
May 11, 2023, 5:28 pm
Editas medicine to present clinical data from the ruby trial of edit-301 for the treatment of severe sickle cell disease at the eha 2023 congress
Company-sponsored webinar to be announced CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage g...
May 11, 2023, 2:32 pm
Theriva biologics reports first quarter 2023 operational highlights and financial results
– Continued to enroll patients in VIRAGE, the phase 2b clinical trial of systemically administered VC...
May 11, 2023, 12:00 pm
Aerami therapeutics to present pharmacokinetic data supporting aer-901 (inhaled imatinib) for pulmonary hypertension at the 2023 american thoracic society (ats) international conference
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing ...
May 11, 2023, 12:00 pm
Monte rosa therapeutics announces first quarter 2023 financial results and provides corporate update
On track to present initial data from phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors i...
May 11, 2023, 11:30 am
Clearside biomedical announces first quarter 2023 financial results and provides corporate update
– phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 – – Positive...
May 11, 2023, 11:05 am
Virios therapeutics announces first quarter 2023 financial results
ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company foc...
May 11, 2023, 11:05 am
Hookipa pharma reports first quarter 2023 financial results and recent business highlights
HOOKIPA on track to report phase 2 data on HB-200 for head and neck cancer in combination with pembroli...
May 11, 2023, 11:01 am
Applied therapeutics reports first quarter 2023 financial results
Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement ...
May 11, 2023, 11:00 am